Low molecular weight additives providing passive surface modification
Endexo® surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood, tissue, or other biological fluids. They are low molecular weight fluoro-oligomeric additives that migrate to the top few nanometers of the device surface during the manufacturing process.
In the presence of blood, the modified surfaces are able to suppress procoagulant protein conformation, reduce platelet adhesion and inhibit platelet activation. In the presence of bacteria mediated fluids the modified surfaces are effective at reducing bacteria adhesion (up to 5 log CFU) and encrustation. Endexo® modified devices reduce thrombosis, infection and biofouling all without the use of drugs.
Endexo® platform technology can be applied to a variety of base polymers (e.g. polyurethane, polysulfone, PVC, polypropylene, and silicone) and manufacturing techniques (e.g. extrusion, solution spinning, and injection molding). Endexo® molecules become an integral part of the base material providing durable surface modification and extended efficacy compared to traditional coatings.
Advantages of Endexo® anti-thrombogenic additive technology
- Passive surface modification
- Permanent presence on all device surfaces
- No impact on device functionality
- No change to existing manufacturing processes
- Compatible with a wide range of base polymers
- Low cost technology
Commercial application of Endexo® anti-thrombogenic additive technology
Average reduction across 8,500 BioFlo™ PICCs studied (as reported by AngioDynamics):
- Reduction of 50% deep vein thrombosis
- Reduction of 59% tissue plasminogen activator
Medical devices portfolio
Anti-thrombogenic additive technology
Visit our onCare platform to access a variety of features and content going beyond what you find on our website.
Health Care Bulletin
Stay up-to-date on industry trends, new Evonik products and services, scientific updates and upcoming seminars.